Form 8-K - Current report:
SEC Accession No. 0001437749-23-021758
Filing Date
2023-08-03
Accepted
2023-08-03 08:45:09
Documents
16
Period of Report
2023-08-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20230802_8k.htm   iXBRL 8-K 25388
2 EXHIBIT 99.1 ex_553964.htm EX-99.1 5594
7 logo.jpg GRAPHIC 5546
8 mbrx20230802_8kimg001.jpg GRAPHIC 3372
  Complete submission text file 0001437749-23-021758.txt   181194

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20230803.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20230803_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20230803_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20230803_pre.xml EX-101.PRE 11584
10 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20230802_8k_htm.xml XML 2560
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 231138272
SIC: 2834 Pharmaceutical Preparations